Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Inotuzumab ozogamicin in the treatment of patients with R/R ALL and extramedullary disease

In this video, Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, highlights the results from a retrospective analysis which investigated the safety and efficacy of inotuzumab ozogamicin in patients with relapsed/refractory (R/R) acute lymphoplastic leukemia (ALL) and extramedullary disease. Dr Papayannidis explains the poor outcome associated with these patients, and then discusses the patient population in this study and dosing schedule used. Dr Papayannidis concludes by explaining the main results of this study, including complete remission, partial remission, and the important anti-leukemic activity that this drug conjugate may provide in cases where patients need to undergo transplantation. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.

Disclosures

Amgen, Pfizer: Advisory Board and Honoraria